医学
肥厚性心肌病
内科学
心脏病学
不利影响
利钠肽
心力衰竭
心室流出道
队列
安慰剂
心肌病
心房颤动
替代医学
病理
作者
Florian Rader,Artur Oręziak,Lubna Choudhury,Sara Saberi,David Fermin,Matthew T. Wheeler,Theodore P. Abraham,Pablo García‐Pavía,Donna R. Zwas,Ahmad Masri,Anjali Owens,Sheila M. Hegde,Tim Seidler,Shawna Fox,Ganesh Balaratnam,Amy J. Sehnert,Iacopo Olivotto
标识
DOI:10.1016/j.jchf.2023.09.028
摘要
Mavacamten treatment showed clinically important and durable improvements in LVOT gradients, NT-proBNP levels, and NYHA functional class, consistent with EXPLORER-HCM. Mavacamten treatment was well tolerated over a median 62-week follow-up.
科研通智能强力驱动
Strongly Powered by AbleSci AI